Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Compiled: THE PEOPLE OF ANAVEX 07/12/19

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 315
Posts 40,492
Boards Moderated 31
Alias Born 09/20/01
160x600 placeholder
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
XenaLives Member Level  Friday, 07/12/19 02:38:24 PM
Re: None
Post # of 231532 
Compiled: THE PEOPLE OF ANAVEX 07/12/19


A 2015 post from blanka highlighting the brilliant minds pushing Anavex forward.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=119221094
______________________________________________________________________________________________
MANAGEMENT:
______________________________________________________________________________________________
Christopher Missling:
Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex®, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of healthcare investment banking at Brimberg & Co. in New York. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.

Missling's unique skill set(from Bourbon_on_my_cornflakes) :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147033809

Missling 2017 research posted on researchgate.net
https://www.researchgate.net/profile/Christopher_Missling

______________________________________________________________________________________________
Walter E Kaufmann:

Dr. Walter E Kaufmann, Chief Medical Officer has over 20 years of experience in clinical studies with focus on developing novel therapies for genetic disorders associated with intellectual disability. Prior to Anavex, Dr. Walter Kaufmann’s was the Director of the Center for Translational Research at the Greenwood Genetic Center, where he also held the Ravenel Boykin Curry Chair in Genetic Therapeutics. He holds adjunct appointments at Emory University School of Medicine, where he is an Adjunct Professor of Human Genetics, and at the University of California Davis School of Medicine, where he is a Visiting Scholar in the Department of Neurology. Dr. Kaufmann is also an Investigator affiliated with the Massachusetts Institute of Technology’s Simons Center for the Social Brain. Before these academic appointments, Dr. Kaufmann was a Professor of Neurology at Harvard Medical School and a Professor of Pathology, Neurology, Pediatrics, Psychiatry, and Radiology at the Johns Hopkins University School of Medicine.

Dr. Kaufmann’s major focus of has been Rett syndrome, a field where he has published extensively on neurobiology and clinical aspects. He served as founder and leader of RettSearch, the international consortium of Rett syndrome clinical researchers. As such, he co-authored the current diagnostic guidelines for the disorder. He also edited the first clinical textbook on Rett syndrome, published in late 2017. Dr. Kaufmann has also served as Co-Principal Investigator of the NIH-funded Natural History Study of Rett syndrome (RDCRN program). Currently, he leads the Rett Syndrome Molecular Biomarkers Working Group for the Rettsyndrome.org foundation and the Rett Syndrome Behaviour Questionnaire Working Group. Dr. Kaufmann has played different roles, including site investigator, Principal Investigator, and DSMB member/chair, in almost 20 drug trials for neurodevelopmental disorders. In this context, he has been involved in virtually all neurobiologically-based drug trials for Rett syndrome.

Dr. Kaufmann has published more than 220 journal articles, most of them original publications. He has also served on several editorial boards and as reviewer for over 100 scientific journals.

Appointment of Walter E Kaufmann, MD as Chief Medical Officer
https://www.anavex.com/anavex-life-sciences-announces-the-appointment-of-walter-e-kaufmann-md-as-chief-medical-officer/

Info on Dr. Kaufmann who will be running the 2-73 Rett Syndrome trial and who is now CMO for Anavex:
http://gcbcenter.kennedykrieger.org/staff.jsp

Until recently, Dr. Kaufmann was the Director of the Center for Translational Research at the Greenwood Genetic Center, where he also held the Ravenel Boykin Curry Chair in Genetic Therapeutics. (video originally posted by kevli33)

______________________________________________________________________________________________
Emmanuel O (“Tayo”) Fadiran:

Dr. Emmanuel O (“Tayo”) Fadiran, Senior Vice President of Regulatory Affairs has over 26 years of experience in government service, of which 24 years were dedicated to the Food and Drug Administration (FDA). Prior to Anavex®, Dr. Fadiran served as Clinical Pharmacology Team Leader at the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER). During his 24 years (1993-2017) tenure at the FDA he reviewed hundreds of NDAs, sNDAs, BLAs, ANDAs and INDs for approval and strategic recommendations for the development of several products across many therapeutic categories. He was also on review teams for several novel therapies including first in class approvals. Dr. Fadiran also led a cross-disciplinary NDA review team and authored the first Cross-Discipline Team Leader (CDTL) review for the Division of the Pulmonary & Allergy Products, Office of Drug Evaluation II, CDER. He was actively involved in the writing, internal/external training and the implementation of the US FDA Guidance for Industry for population pharmacokinetics.

Dr. Fadiran has been involved in the formulation of significant strategic FDA regulatory initiatives including serving as a member of the Senior Management Teams for the DaHampta Standard (Janus) and Sentinel Initiatives. He was an active member of the FDA Senior Science Council working group for the creation and launching of the FDA’s Strategic Plan for Regulatory Science in 2012. Recently he has played an active role in the development of the Comprehensive in vitro Proarrhythmia Assay (CiPA) for future replacement of the thorough QT studies. As a long-term member of the FDA Institutional Review Board (IRB) he actively contributed to the development of standard operating procedures (SOP) for the committee.

Dr. Fadiran holds a BS (Pharmacy) and MS from Obafemi Awolowo University, Ile-Ife, Nigeria and a PhD in Pharmaceutical Sciences from the University of Strathclyde, Glasgow, UK. Dr. Fadiran is a recipient of the prestigious Fogarty International Fellowship of the National Institutes of Health (NIH) (1991-1993) as well as numerous awards from the FDA, among them the Commissioner’s Award of Excellence, in recognition of his outstanding contributions to regulatory review of applications and development of regulatory guidance and policies.

See also:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147996796
______________________________________________________________________________________________
Daniel Klamer:

Dr Daniel Klamer, Vice President of Business Development and Scientific Strategy of Anavex, has more than 15 years of experience in neuroscience and the orphan disease space, with acquisition, partnering and R&D experience in Europe and the USA. Prior to Anavex he worked at Retrophin and Neurosearch Sweden. At Neurosearch Sweden, Dr Klamer led and evaluated multiple discovery-phase neuropharmacological research products with an emphasis on strategic evaluation of preclinical and clinical development.

Dr. Klamer earned his PhD in Pharmacology at The Sahlgrenska Academy at University of Gothenburg, Sweden, his MBA at Fordham Gabelli School of Business, and his Post-Doctoral training at the Department of Psychiatry, Yale University School of Medicine. In addition, Dr. Klamer holds a position as an Associate Professor at the Department of Pharmacology at The Sahlgrenska Academy at the University of Gothenburg.

February 19-21, 2019, Anavex participated in the 7th World CNS Summit - Targeting Neurodegenerative Diseases.
https://www.nyas.org/events/2018/alzheimer-s-disease-therapeutics-alternatives-to-amyloid/?tab=agenda
From the event’s description:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144414392';
Klamer paper on the topic above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147056161

See patent section for new info on patents for pain and Alzheimer's treatment protocol.

______________________________________________________________________________________________
Stephen Toutain:

Stephan Toutain, Senior Vice President of Operations, brings more than 25 years of drug development, general management, operations, commercial development, market access, and sales and marketing leadership with particular expertise in neurology and orphan drug markets globally. Before joining Anavex, he held the role of CCO at Interleukin Genetics. He also worked with Alnylam Pharmaceuticals to build its early access program. Previously, he led Global Commercial Development for Sarepta Therapeutics and served as General Manager for Alexion Pharmaceuticals in Europe. Mr. Toutain has also held various U.S. commercial, marketing and product management positions with Alexion Pharmaceuticals, Celgene Corporation, and Johnson & Johnson. He received a Master of Business Administration from the University of North Carolina, and a Master of Engineering in Biotechnology from the University of Nancy II in France.

Stephan Toutain appointed Senior Vice President of Operations
https://www.anavex.com/anavex-life-sciences-strengthens-management-team-board-directors/

Toutain's linked in profile lists expanded access
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147884394

Toutain DD
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147172095
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146739245

______________________________________________________________________________________________
BOARD OF DIRECTORS:
______________________________________________________________________________________________
Christopher U. Missling:
(see above)
______________________________________________________________________________________________
Claus van der Velden:

Claus van der Velden, PhD, brings significant expertise in accounting and is currently corporate head of Management Accounting, Internal Audit and Risk Management at Stroeer SE & Co KGaA, a publicly listed $3bn media company. Previously, Dr. van der Velden served as Director, Corporate Business Controlling for the Nutrition & Health business unit at Cognis, a worldwide supplier of global nutritional ingredients and specialty chemicals with about $3bn sales. In this position, he was also a compliance representative and a member of the global leadership team. After the acquisition of Cognis by BASF, he was responsible for the management accounting processes of the $2bn BASF Nutrition & Health division, developing and producing mostly natural-source ingredients for the food and healthcare industries. Dr. van der Velden started his career as a strategy consultant at an international marketing and strategy consultancy firm. He studied in Kiel and Stockholm and received a degree in economics from the University of Kiel and later obtained his doctorate from the WHU-Otto Beisheim School of Management.

Claus van der Velden appointed to Board of Directors
https://www.anavex.com/anavex-life-sciences-strengthens-management-team-board-directors/

______________________________________________________________________________________________
Peter Donhauser:

Peter Donhauser, D.O., a director of Anavex®, has more than 20 years of expertise in clinical research followed by practicing osteopathic medicine with an integrated medical approach in private practice since 2000. He worked at the University Hospital of Munich in the fields of geriatrics and neuromusculoskeletal diseases. During this time, he was a clinical trial investigator in multiple Phase 3 studies, including studies sponsored by Merck Sharp & Dohme/Merck, Boehringer Mannheim/Roche, Servier and Sanofi. He received his human medicine degree at the University of Munich and Doctor of Osteopathic Medicine (D.O.) from the DAAO and EROP at the Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania.

______________________________________________________________________________________________
Steffen Thomas:

Steffen Thomas, PhD, a director of Anavex®, has over 15 years of experience as a European patent attorney and is currently practicing at Epping Hermann Fischer, a major intellectual property law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas’ legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich.

______________________________________________________________________________________________
Elliot Favus:

Elliot Favus, MD, a director of Anavex®, is Chief Executive Officer of Favus Institutional Research, a healthcare research firm serving institutional investors. He has been a healthcare equity research analyst on Wall Street since 2006, starting at Lazard Capital Markets and subsequently at Och-Ziff Capital Management Group. Prior to working on Wall Street, Dr. Favus was an Instructor in medicine at Mount Sinai School of Medicine in New York. He attended the University of Michigan (BA, 1996), the University of Chicago Pritzker School of Medicine (MD, 2001) and the NYU-Bellevue Hospital Internal Medicine Residency Program (2004). He is board-certified in Internal Medicine (2004) and has 10 years of basic science laboratory experience working on human genetics projects at Harvard Medical School, the University of Chicago and the University of Pittsburgh.
______________________________________________________________________________________________
Tom Skarpelos:

Mr. Skarpelos, a director of Anavex®, is a self-employed investor with 17 years of experience working with private and public companies. For the past 10 years, he has been focused on biotechnology companies involved in drug discovery and drug development projects. Mr. Skarpelos was engaged as a consultant to Anavex®Life Sciences for one year effective August 2, 2010. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos is a founder of Anavex®Life Sciences, and is its largest shareholder.

______________________________________________________________________________________________
SCIENTIFIC ADVISORY BOARD:
______________________________________________________________________________________________
Jeffrey Cummings:


A clinical expert on the Anavex® Scientific Advisory Board, Dr. Jeffrey Cummings is Professor of Neurotherapeutics and Drug Development in the Neurological Institute, Cleveland Clinic. He is Director of the Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada and Cleveland, Ohio. Dr. Jeffrey Cummings graduated magna cum laude from the University of Wyoming, Laramie and obtained his MD degree (with thesis) from the University of Washington, Seattle. He completed internship at Hartford Hospital in Hartford, Connecticut and did his Neurology residency at Boston University, Boston, Massachusetts. Dr. Cummings was formerly the Augustus S. Rose Professor of Neurology and Professor of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine at UCLA, Los Angeles, California, USA. He was the Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. Dr. Cummings has expertise in neuropsychiatric assessment, outcomes in clinical trials, clinical trial design and analysis, and global clinical trials. He is a frequent consultant to industry. Dr. Cummings has authored more than 500 peer-reviewed papers and 30 books on Alzheimer’s disease, neuropsychiatry, and clinical trials. Dr. Cummings’ interests embrace the neuropsychiatry of neurologic disorders, biomarkers for neurodegenerative diseases, and clinical trials and drug development for neurologic diseases.

See also:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149464055
______________________________________________________________________________________________
Paul Aisen:

A clinical expert on the Anavex® Scientific Advisory Board, Dr. Aisen is a leading clinician and researcher in Alzheimer’s disease clinical trials and is founding director of the University of Southern California (USC) Alzheimer’s Therapeutic Research Institute in San Diego. Previously, he was on the faculty of the University of California, San Diego (UCSD) School of Medicine’s Department of Neurosciences. His primary research interests focus on the development of new strategies for the treatment of Alzheimer’s disease. Since 2007, Dr. Aisen has been Director of the Alzheimer’s Disease Cooperative Study, a consortium funded by the National Institute on Aging (NIA) to develop assessment instruments and conduct clinical trials. Dr. Aisen is Associate Editor of Alzheimer’s Research and Therapy, a major international peer-reviewed journal, and sits on the editorial board of BMC Medicine. He has published more than 180 peer-reviewed papers.

Paul Aisen - Ethics issues:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149781017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149781193

Anavex, ACTC and Paul Aisen:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147089981

Bloomberg board links for Paul Aisen:
https://www.bloomberg.com/research/stocks/people/relationship.asp?personId=20759834&ticker=AVXL&previousCapId=26606238&previousTitle=OrgSyn%2520Laboratory%252C%2520Inc.

Aisen is a director of the ACTC also -
https://act-ad.org/about-act-ad/science-advisory-board/

March 2019 discussion of ACTC begins here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147409548

Historical discussions about Aisen:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148133076

PR appointing Aisen to SAB in 2011:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147411285

See the bottom of this post on Aisen board links:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147360088

Aisen and the ACTC:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147409548
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147409564

Aisen working on accelerating recruitment in the U.S.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144345752

ACTC Ops Plan with the initial focus at USC with Dr Paul Aisen's group. (from Talon38 8/18 post)
http://grantome.com/grant/NIH/U24-AG057437-01

______________________________________________________________________________________________
Norman Relkin:

A member of the Scientific Advisory Board, Dr. Relkin is an internationally recognized expert on Alzheimer’s disease and related disorders. An American Board of Psychiatry and Neurology-certified neurologist, he graduated from Yale and earned MD and PhD degrees from New York’s Albert Einstein College of Medicine. Dr. Relkin is an Associate Professor of Neurology at the Weill Cornell Medical College and Founding Director of the Weill Cornell Memory Disorders Program. He has 20+ years of clinical trials experience, serving as principal investigator in over 20 therapeutic studies, including multi-center trials he designed. Over the past decade, Dr. Relkin pioneered the study of naturally occurring human antibodies for the treatment of Alzheimer’s. He led all three clinical trial phases of Intravenous Immunoglobulin as a potential Alzheimer’s treatment, including the pivotal National Institutes of Health (NIH) and Baxter co-sponsored study carried out at 45 sites (US and Canada). The author of numerous publications on neurodegenerative and traumatic disorders of the brain during the past 25 years, Dr. Relkin sits on editorial boards for three scientific journals. Additionally, he has been a reviewer for NIH and funding agencies in Europe and Australia, and has been a long-standing member of the Weill Cornell Institutional Review Board. In 2012, he was elected to the Board of Directors of The American Federation for Aging Research.
______________________________________________________________________________________________
Dag Aarsland:

Dr Aarsland is Professor and the Head of Department of Old Age Psychiatry at the Institute of Psychiatry, Psychology & Neuroscience, King’s College London, UK. Professor Aarsland is also consultant psychiatrist at the Mental Health for Older Adults and Dementia, South London & Maudsley NHS Foundation Trust, where he leads the Parkinson Spectrum Memory Clinic. He earned medical degrees from Universities of Bochum, Germany and Oslo, Norway, with training as a specialist in psychiatry and geriatric psychiatry. He founded and still leads the nationally acclaimed Centre for Age-Related Disease at Stavanger University Hospital. He completed his PhD and became appointed Associate Professor and later Full Professor of Old Age Psychiatry at the University in Bergen, Norway. Later he became Professor at the University of Oslo, before becoming appointed as Professor of Clinical dementia research at the Alzheimer’s Disease Research Centre at the prestigious Karolinska Institute in Stockholm, Sweden. After working in Sweden for five years he moved to his current position at King’s College London. Professor Aarsland developed and led the European Consortium for dementia with Lewy bodies (DLB), with more than 25 centers across 13 European countries, with a common database of more than 1,200 DLB patients, by far the largest DLB sample in the world. He developed a Parkinson-spectrum Memory Clinic focusing on Parkinson’s disease and dementia with DLB patients. Professor Aarsland played a central role in the study and subsequent paper that lead to the licensing of rivastigmine for Parkinsonian dementia. Professor Aarsland has published more than 400 scientific papers and numerous books and served as an invited speaker at frequent psychiatric and neurological international scientific conferences.

November 2018 - New SAB member Dr. Dag Aarsland, support for current and future pipeline:
https://globenewswire.com/news-release/2018/11/08/1647793/0/en/Anavex-Life-Sciences-Strengthens-its-Scientific-Advisory-Board-with-Distinguished-Researcher-for-Clinical-Treatment-of-Parkinson-s-Disease-Dementia-PDD.html

Eisai is connected with one of Anavex scientific advisors. (Dag Aarsland ) in Lisbon.
Thursday, March 28th, 17:20 - 19:20, Auditorium VI+VII
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147789180

Alzheimer’s and Parkinson’s Disease: Similarities and Differences (Aarsland and Weintraub have AVXL affiliation)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147932208

Alzheimer’s and Lewy Body Dementia: Similarities and Differences (from kevli33)

______________________________________________________________________________________________
Daniel Weintraub:

A member of the Scientific Advisory Board, Dr. Weintraub is professor of psychiatry at Perelman School of Medicine at the University of Pennsylvania in Philadelphia. He is professor of psychiatry and neurology at Penn and psychiatrist at the Parkinson’s Disease Research, Education and Clinical Center (PADRECC) at the Philadelphia Veterans Affairs Medical Center. A geriatric psychiatrist, he conducts clinical research in the psychiatric and cognitive complications of Parkinson’s disease and is author of more than 100 journal articles, reviews and book chapters. Dr. Weintraub completed a NIMH Career Development Award titled “Depression Diagnosis and Treatment in Parkinson Disease” and has been PI on grants from the VA, Penn, The Michael J. Fox Foundation for Parkinson’s Research and several industry-sponsored studies. He is also the current Clinical Core Leader of the Penn Udall Center focused on cognition in Parkinson’s disease. Dr. Weintraub is Associate Editor for Movement Disorders journal, was formerly on the Executive Committee of the Parkinson Study Group (PSG), has been a member of four Movement Disorder Society (MDS) task forces to revise and make recommendations for the assessment of cognitive and psychiatric symptoms in Parkinson’s disease and was chair of the Psychiatry Subgroup of the NINDS Common Data Elements (CDE) project.

Alzheimer’s and Parkinson’s Disease: Similarities and Differences (Aarsland and Weintraub have AVXL affiliation)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147932208

______________________________________________________________________________________________
Jacqueline French:

A member of the Scientific Advisory Board, professor in the Department of Neurology at New York University (NYU), Co-Director of Epilepsy Research and Clinical Trials at NYU’s Comprehensive Epilepsy Center and Director of the Epilepsy Study Consortium, Dr. French is an award-winning, internationally recognized expert on epilepsy, new therapeutic interventions and clinical trial methodology. She plays an ongoing leadership role in the area of development of new therapeutics for epilepsy, including co-directing a bi-annual symposium on trial design and its implications and holds positions on committees of the American Academy of Neurology (AAN), where she has also co-authored several AAN clinical practice guidelines. Broadly published, including numerous research articles, editorials and chapters, her writings have been featured in respected publications including The New England Journal of Medicine, Neuron, Neuro Image, Epilepsy Currents and Lancet Neurology. She has also edited two books on epilepsy and is an in-demand global speaker on antiepileptic drug therapeutics and related topics. Previously, Dr. French was Assistant Dean for Clinical Trials at the University of Pennsylvania, a recent President of the American Epilepsy Society, Secretary of the American Society of Experimental Neurotherapeutics, and worked with the US Food and Drug Administration (FDA) developing new trial designs for the approval of antiepileptic drugs. Dr. French trained in Neurology at Mount Sinai Hospital (New York), and did her fellowship training in EEG and epilepsy at Mount Sinai Hospital and Yale University. She was the recipient of the Epilepsy Foundation’s 2013 Hero of Epilepsy Award, honoring her longtime contributions to epilepsy research and clinical trials, alongside her significant impact on the epilepsy community.


"We are excited to welcome Jacqueline as a Scientific Advisor. Her work has led to ground-breaking epilepsy treatments and she is recognized for pioneering the clinical care of seizures," said Christopher U. Missling, President and Chief Executive Officer of Anavex. "We believe Jacqueline's expertise, as well as her background in neurology, will offer significant value as we advance our potential platform drug ANAVEX 2-73 across additional indications beyond Alzheimer's, including epilepsy."

Dr. French plays an ongoing leadership role in the area of development of new therapeutics for epilepsy. She co-directs a bi-annual symposium on trial design and its implications and holds positions on committees of the American Academy of Neurology (AAN), where she has also co-authored several AAN clinical practice guidelines. In addition, Dr. French is broadly published, having written numerous research articles, editorials and chapters. Her writing has been featured in respected publications including The New England Journal of Medicine, Neuron, Neuro Image, Epilepsy Currents and Lancet Neurology. She has also edited two books on epilepsy and is an in-demand global speaker on antiepileptic drug therapeutics and related topics.

https://www.globenewswire.com/news-release/2015/03/12/714717/10124304/en/Anavex-Appoints-Epilepsy-and-Clinical-Trial-Methodology-Expert-to-Scientific-Advisory-Board.html

SAB member Jacquelin French, video discussing Seizures and Epilepsy: (from kevli33)


Board Post on recent paper by Tangui Maurice :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147955142

More research from Tangui Maurice:
http://www.anavex.com/wp-content/uploads/9A9B8DB2.pdf
______________________________________________________________________________________________
EMPLOYEES:
______________________________________________________________________________________________
Alani Selvy:

New hire noted by kevli33 - no public info from the company as of 04/05/19
https://www.linkedin.com/in/alani-selvey-9117897/?trk=org-employees_mini-profile_title
https://www.researchgate.net/profile/Alani_Selvey
___________________________________________________________________________________________________________________
Sandra Boenisch:
Boenisch Sandra 6/4/2019 options grant
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149255182

______________________________________________________________________________________________
RESERARCHERS and COLLABORATORS:
______________________________________________________________________________________________
Alexandre Vamvakides:

Quote:
Geneva, Switzerland — January 31, 2007 — Anavex Life Sciences Corp. (OTCBB: AVXL) (the “Company”) announces that it has acquired a portfolio of three patents and one patent application covering drug candidates indented to be further developed through commercialization targeting the areas of neurological diseases and cancer. The patents were assigned by Dr. Alexandre Vamvakides, of Paris, France, who has been appointed as Chief Scientific Officer and member of the Board of Directors.

Under the terms of the acquisition, Anavex is to pay for the development of the compounds by expending not less than $200,000 US per annum. Dr. Vamvakides will lead the development project and will receive 6% royalties on the total net income resulting from successful exploitation of the assigned patents. The Company endeavors to further develop the appropriate compounds utilizing various research facilities worldwide.

Prior to joining Anavex Life Sciences, Dr. Vamvakides has spent 30 years in research focusing on the therapeutic/pharmacological areas of nootropes, anti-neurodegenerative (anti-Alzheimer), antiepileptic, antidepressive, and prototype molecules. During his career, Dr. Vamvakides has been published over 80 times in highly respected Medical/Scientific journals. In the past 30 years, Dr. Vamvakides has pioneered his expertise at the Institut National de la Sante et de la Recherche Medicale (INSERM) in Paris France, at the University of Athens (Greece) as well as at Chropi Pharmaceuticals (Piraeus, Greece), Ciba-Geigy (Basel, Switzerland) and Sanofi (Montpellier, France) for the development of new concepts in the aforementioned therapeutic/pharmacological areas.


https://www.anavex.com/anavex-life-sciences-corp-acquires-a-portfolio-of-patents-and-appoints-dr-alexandre-vamvakides-as-cso-and-director/


______________________________________________________________________________________________
Rudolph Tanzi:

Fortunately, Anavex leadership has world wide prominence:

PBS quoting Tanzi (thanks to Kevli33):

Quote:
But by the time a cognitive assessment picks up on symptoms of Alzheimer's disease and dementia, it's usually already too late for meaningful treatment, said Rudolph Tanzi, professor of neurology at Harvard University who also co-directs the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital. Two decades before symptoms of Alzheimer's reveal themselves, the brain already is changing.

"We need to know how to treat a person at the right time to stop the disease from becoming symptomatic and leading to brain waste and dementia."
Rather than solely relying on less precise assessments, "we need to know how to treat a person at the right time to stop the disease from becoming symptomatic and leading to brain waste and dementia," Tanzi said.

What we should be doing, he said, is encourage more cognitive assessments but also further develop tests and medications to diagnose and treat Alzheimer's before a person loses cognitive abilities.

Tanzi has researched the illness since the early 1980s and was part of the team that discovered the three genes linked to early onset of Alzheimer's disease. In fact, genes may play a bigger role in the development of Alzheimer-linked plaques and tangles in the brain than previously understood, according to recent research.



https://www.pbs.org/newshour/health/why-the-number-of-americans-with-alzheimers-could-more-than-double-by-2050



______________________________________________________________________________________________
Tanya Simuni:

Tanya Simuni, MD, is AC Nielsen Professor of Neurology and Director, Parkinson’s Disease and Movement Disorders Program at Northwestern University Feinberg School of Medicine, Chicago, Illinois
Dr. Simuni earned her Bachelor of Science and medical degrees from Leningrad Medical School, Russia. She completed a neurology residency and clinical neurophysiology fellowship at Temple University, Philadelphia, and a fellowship in movement disorders at the University of Pennsylvania, Philadelphia. She joined the neurology faculty at Northwestern University in 2000. She has built a multidisciplinary Parkinson’s disease center that has been designated a Center of Excellence by the National Parkinson’s Foundation.

Dr. Simuni’s research interests include experimental pharmacology, early diagnosis, non-motor manifestations and surgical management of Parkinson’s disease. As principal or co-investigator of numerous NINDS, MJFF and industry sponsored clinical trials, Dr. Simuni has done extensive research on the treatment of Parkinson’s disease focused on studying potential disease modifying strategies. Dr. Simuni is the principal investigator on the NINDS-funded, multicenter Phase III study of the potential disease modifying agent, isradipine.

Dr. Simuni has received several prestigious awards including the Dixon Foundation Innovation Award, National Parkinson’s Foundation Research Awards, Northwestern Department of Neurology Teacher of the Year Award, and the Northwestern Medical Foundation Award for Excellence in Clinical Leadership. Dr. Simuni dedicates substantial amount of her professional time to teaching and mentoring, and has served as the neurology residency program director at Northwestern.

______________________________________________________________________________________________
Kalpana M. Merchant:

Kalpana M. Merchant, PhD, President and CSO, TransThera Consulting Co.; Adjunct Professor of Neurology at Northwestern University Feinberg School of Medicine and Adjunct Professor of Biology at Indiana University Purdue University at Indianapolis
Dr. Kalpana Merchant has deep expertise in the neurobiology of chronic neurodegenerative and psychiatric disorders. She has nearly 25 years of experience in drug discovery and development with a special emphasis on translational strategies that improve the success rate of drug development.

In March 2014, Kalpana established a life sciences business that provides consultancy services to non-profit institutions and start-up pharmaceutical/ biotechnology companies. She continues to remain engaged in training and mentoring of graduate students, postdoctoral scientists and junior faculty through her academic positions.

Prior to her consulting activities, Kalpana worked in the US pharmaceutical industry as a scientific contributor and in strategic leadership/ management roles. She retired in March 2014 from Eli Lilly and Company where she was the Chief Scientific Officer for Tailored Therapeutics – Neuroscience, accountable for scientific and business strategies to deliver personalized therapies and associated biomarkers for the neuroscience portfolio – from discovery through Phase III.

Kalpana received her PhD in neuropharmacology from the University of Utah. Following a postdoctoral research fellowship at University of Washington, she was appointed Assistant Professor of Psychiatry at the same institution. She was recruited to Eli Lilly in 2003 from Pharmacia Corp., where she had contributed to neuroscience drug discovery research for 10 years.

Kalpana is engaged in the wider scientific community via her service on the National Center for Advancing Translational Sciences (NCATS) Advisory Council and the Cures Acceleration Network Review Board for the National Institutes of Health (NIH), as an advisor to the Michael J Fox Foundation for Parkinson’s Research, membership of The Wellcome Trust Review Board as well as several professional societies.

______________________________________________________________________________________________ _
Terry O'Brien:

Leading the Aussie Rett trial.

Putting a face to the name (Prof. Terry O'Brien)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149294128
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149294230




In Peace, In War
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist